%0 Case Reports
%T Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
%A Hagihara Y
%A Suetsugu T
%A Uto H
%A Kozono T
%A Masada Y
%A Satozono Y
%A Shinmura M
%A Koreeda Y
%A Mizuno K
%A Inoue H
%J Respir Investig
%V 62
%N 1
%D 2024 Jan 3
%M 37925883
暂无%R 10.1016/j.resinv.2023.09.006
%X Osimertinib has demonstrated efficacy as the first- and second-line treatment for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. However, EGFR-mutant NSCLC cells often acquire resistance to osimertinib. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation (BRAF V600E) was detected in a re-biopsy (LC-SCRUM-TRY testing) of a patient with advanced lung adenocarcinoma who was resistant to osimertinib treatment. Currently, the patient is receiving dabrafenib/trametinib combination therapy and is under observation; a slight shrinking effect of cancer has been observed.